BMO Capital analyst Michael Zaremski raised the firm’s price target on RenaissanceRe to $295 from $216 and keeps an Outperform rating on the shares. The firm cites the company’s earnings call which included updated disclosure and guidance on the recent closed acquisition of Validus, the analyst tells investors in a research note. BMO is also raising its FY24 EPS view to $37.05 from $33.70 and its FY25 view to $38.25 from $34.89, primarily driven by including more insurance premiums and investment income acquired through the Validus acquisition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RNR:
- RenaissanceRe reports Q4 operating EPS $11.77 vs $7.33 last year
- RenaissanceRe price target lowered to $281 from $287 at BofA
- RenaissanceRe initiated with a Market Perform at TD Cowen
- RenaissanceRe reinstated with Neutral from Underweight at JPMorgan
- RenaissanceRe initiated with bearish view at Evercore ISI, here’s why